biotech / news / / CNBC
Eli Lilly will pay $3.25 billion upfront for Kelonia Therapeutics.
Eli Lilly will acquire Kelonia Therapeutics in a deal valued up to $7 billion.
KEY POINTS
- Kelonia's in vivo CAR-T technology reprograms T-cells inside the body via a one-time IV therapy.
- Unlike existing ex vivo CAR-T treatments, Kelonia's therapy requires no cell harvesting or preconditioning.
- Lilly aims to broadly enter hematology with Kelonia's treatment, targeting community clinics beyond academic centers.
- The acquisition is expected to close in the second half of 2026.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →